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Cardiac resynchronisation therapy (CRT) on top of optimal
heart failure medication has a proven benefit on long-term
clinical outcome in symptomatic patients with reduced left
ventricular ejection fraction (LVEF) and electrical dyssyn-
chrony. The first prospective randomised trial to show a
significant mortality reduction in patients with heart fail-
ure of New York Heart Association (NYHA) class III and
IV was the landmark trial CARE-HF [1]. Of note, in that
study CRT pacemakers (CRT-P), but not CRT defibrilla-
tors (CRT-D) were implanted. Thereafter, the addition of
CRT to an implantable cardioverter-defibrillator (ICD) in
patients with milder NYHA class II or III heart failure, a
wide QRS complex and left ventricular systolic dysfunc-
tion showed reduced rates of death and hospitalisation for
heart failure [2]. This evidence is reflected in the current
guidelines of the European Society of Cardiology (ESC)
on cardiac pacing and CRT published in 2013 [3]. CRT is
recommended in chronic heart failure patients with LVEF
≤35%, who remain in NYHA functional class II, III or am-
bulatory IV despite adequate medical treatment, and in pa-
tients with left bundle-branch block (LBBB) and QRS du-
ration >150 ms (class I indication with level of evidence
A). For patients with LBBB and a QRS duration of 120 to
150 ms a class I indication with level of evidence B is giv-
en. Patients without LBBB and with QRS duration >150
ms represented a class IIa indication with a level of evi-
dence B.
Whether CRT is beneficial in patients with systolic heart
failure and a QRS duration of less than 130 ms but evi-
dence of dyssynchrony on echocardiography was studied
in the EchoCRT trial [4]. CRT in these patients, however,
did not reduce the rate of death or hospitalisation for heart
failure and even showed increased mortality. In contrast,
for patients with atrioventricular block and a pacing indi-
cation, a moderately reduced LVEF of <50% and NYHA
class I–III heart failure, biventricular pacing was superior
to conventional right ventricular pacing [5].
Randomised controlled trials (RCTs) form the basis for
recommendations and guidelines. However, one disadvan-
tage of RCTs is the exclusion of high-risk patients [6].
Therefore, surveys and registries without exclusion criteria
may provide interesting and important data on daily clini-
cal practice.
The European CRT Survey II included more than 11,000
CRT patients within 42 ESC member countries between
October 2015 and December 2016, with the aim to collect
real-life data on contemporary patient selection, implanta-
tion and follow-up practice [7]. This survey permits assess-
ment of guideline adherence and demonstrates variations
among different countries.
Currently in Swiss Medical Weekly, Zeljkovic and co-
workers compare the characteristics of Swiss CRT recipi-
ents with the overall European CRT population in the Eu-
ropean CRT Survey II [8]. They found that Swiss CRT
patients are older (71 vs 68.5 years), less symptomatic
and suffer more often from comorbidities including more
chronic kidney disease. Most often CRT-D systems were
implanted (in two thirds), but Swiss patients more often
received CRT-P systems than their European counterparts.
A strength of this survey and the comparison is the high
number of patients included (overall 11,088 patients from
42 countries, including 320 patients from Switzerland) and
the timely inclusion period between 2015 and 2016, which
allow reflection on the adherence to the current guidelines
published in 2013.
The higher rate of patients implanted with CRT-P systems
may be explained by the older age of the patients and the
higher rate of competing risk factors for death, where the
effect of an additional defibrillator function may be mini-
mal or even absent. Therefore, evidence seems to guide the
decision as to which device should be implanted, but not
the fact that the reimbursement system in Switzerland al-
lows for easy access to all technologies. Whether different
attitudes of the patients to the mode of death may play a
role is speculative and deserves further investigation. Al-
though Swiss patients were older and had more comor-
bidities, they were less often hospitalised for heart failure
before implantation, reflecting a better access to ambu-
latory healthcare services. Easy access to the latest tech-
nologies and medication is also reflected by the fact that
a higher proportion of Swiss patients were implanted with
quadripolar leads and that they received novel oral antico-
agulants (NOACs), if anticoagulation was indicated, more
often than patients in other European countries. Swiss pa-
tients less often had the classical indication of heart failure
with a wide QRS complex, and less often complete LBBB,
but more often a higher degree atrioventricular-block with
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CRTs employed for expected dyssynchrony due to a high
amount of right ventricular pacing. An explanation may be
faster transition of recent evidence into current practice,
and a reimbursement system that allows faster adoption of
new evidence. It will be interesting to see whether newest
evidence from the DANISH trial will translate into current
practice in a similar way [9]. In that study, prophylactic
ICD implantation in patients with symptomatic systolic
heart failure not caused by coronary artery disease was
not associated with a significantly lower long-term rate of
death from any cause than was usual clinical care.
Finally, there are also some similarities between Switzer-
land and the other European countries. In both, women
were underrepresented (24 vs 24%), despite the fact that
women, including those with narrower QRS (130–150 ms),
seem to have a higher benefit from CRT [10]. The under-
treatment of women in the field of cardiovascular diseases
is known, but not fully understood and should be addressed
in further research.
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